180 related articles for article (PubMed ID: 30352394)
1. Management of prolactinoma: a survey of endocrinologists in China.
Ji L; Yi N; Zhang Q; Zhang S; Liu X; Shi H; Lu B
Endocr Connect; 2018 Oct; 7(10):1013-1019. PubMed ID: 30352394
[TBL] [Abstract][Full Text] [Related]
2. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
3. Management of prolactinomas in Brazil: an electronic survey.
Vilar L; Naves LA; Casulari LA; Azevedo MF; Albuquerque JL; Serfaty FM; Pinho Barbosa FR; de Oliveira AR; Montenegro RM; Montenegro RM; Ramos AJ; Dos Santos Faria M; Musolino NR; Gadelha MR; Boguszewski CL; Bronstein MD
Pituitary; 2010 Sep; 13(3):199-206. PubMed ID: 20107911
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
7. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
9. Management of prolactinomas during pregnancy -- a survey of four Canadian provinces.
Almalki MH; Ur E; Johnson M; Clarke DB; Imran SA
Clin Invest Med; 2012 Apr; 35(2):E96-104. PubMed ID: 22469109
[TBL] [Abstract][Full Text] [Related]
10. Surgical management considerations in cystic prolactinomas-a single center case series.
Nevzati E; Chatain GP; Carr SB; Lillehei KO; Kerr JM
Endocrine; 2020 Jan; 67(1):58-66. PubMed ID: 31773633
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
12. [Prolactinoma].
Glezer A; Bronstein MD
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Pekić S; Medic Stojanoska M; Popovic V
Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
[TBL] [Abstract][Full Text] [Related]
16. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.
Garcia MM; Kapcala LP
J Endocrinol Invest; 1995 Jun; 18(6):450-5. PubMed ID: 7594240
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma and pregnancy: From the wish of conception to lactation.
Maiter D
Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
19. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.
Zárate A; Canales ES; Cano C; Pilonieta CJ
Acta Endocrinol (Copenh); 1983 Oct; 104(2):139-42. PubMed ID: 6356741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
